Syneos Health Stock

Syneos Health Equity

Delisted·Sep 29, 2023

The The Equity of Syneos Health (SYNH) as of Aug 17, 2026 is 3.50 B USD. In the previous year, The Equity was 3.41 B USD — a change of 2.42% (higher).

Equity

3.50 BUSD

YoY

2.42%

Last updated:

In 2026, Syneos Health's equity was 3.50 B USD, a 2.42% increase from the 3.41 B USD equity in the previous year.

Access this data via the Eulerpool API

Syneos Health Stock analysis

What does Syneos Health do? Syneos Health is a US-based pharmaceutical and biotech service company. They specialize in providing integrated solutions for clinical research, commercial services, and data analysis. The company was founded in 2017 through the merger of two leading service companies, INC Research and inVentiv Health. Today, Syneos Health is one of the largest providers of clinical and commercial services in the pharmaceutical and biotech industry. They support their customers in the development and marketing of medications, diagnostics, and medical devices by offering a wide range of services including planning and conducting clinical trials, data analysis and management, and product marketing. Syneos Health operates in four business areas: clinical solutions, commercial solutions, consulting services, and clinical data analysis. Their primary focus is on delivering customer-centric services that cover various aspects of the pharmaceutical and biotech industry value chain. Within their clinical and medical segment, they conduct clinical trials and provide supporting services. They have expertise in clinical research and have successfully executed numerous studies. Syneos Health also offers consulting services in the areas of data management systems and clinical trials. In the commercial segment, they assist customers with marketing, sales promotion, and channel management to ensure the successful launch and sales of products. They provide training for sales staff, market research and analysis, and continuous support from sales and marketing experts. Their consulting services encompass strategy consulting, market research, branding, and communication. They also assist with the development, implementation, and validation of clinical trials, literature research, and regulatory support. Syneos Health's clinical data analysis involves analyzing large data sets to gain insights into the healthcare industry. They utilize cutting-edge technologies such as Big Data Analytics and Machine Learning to provide customers with valuable insights that aid in decision-making. In addition to clinical trials and consulting, Syneos Health offers modern technologies for the development and marketing of medications. This includes Virtual Reality solutions, personalized patient programs for chronic disease treatment, and digital platforms for data collection, analysis, and management. Syneos Health serves globally operating pharmaceutical and biotech companies that rely on their services to develop and market innovative medications and treatment methods. Customers value Syneos Health's expertise and trust that the company will help them successfully bring their products to market. Overall, Syneos Health is a leading company in the pharmaceutical and biotech industry. Their integrated services enable customers to work faster and more effectively. By combining expertise in clinical research, commercial solutions, consulting services, and clinical data analysis, Syneos Health offers innovative and successful solutions to its customers. Syneos Health is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Syneos Health's Equity

Syneos Health's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Syneos Health's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Syneos Health's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Syneos Health's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Syneos Health’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Syneos Health stock

The Equity of Syneos Health is 3.50 B USD in 2026.

The Equity of Syneos Health changed from 3.41 B USD to 3.50 B USD, representing a 2.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Syneos Health since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Syneos Health historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Syneos Health

All Key Metrics — Syneos Health